To our knowledge, whilst there are no established MCIDs for other investigated analytes, results from small sample linear regression analysis indicate that changes in IL-1β by 0.54 pg/ml may be clinically meaningful for reductions in cancer incidence in a clinical population (chronic pulmonary disease) (Zhan et al., 2018). This evidence concerns the gene IL1B and cancer.